INTRODUCTION
============

Regulatory T (T~reg~) cells have potent immunosuppressive ability and are vital for maintaining immune homeostasis and peripheral tolerance. T~reg~ cell transcriptional program is dependent on the transcription factor (TF) Foxp3, which is also essential for their development and suppression function ([@R1]--[@R3]). Alteration in the human TF FOXP3 leads to fatal autoimmune disease, causing immune dysregulation, polyendocrinopathy, enteropathy, X-linked (IPEX) syndrome in humans and mice (Scurfy) ([@R4]--[@R7]). Despite the indispensable role of Foxp3, Foxp3 alone is not sufficient to induce the T~reg~ cell program ([@R8]), and other TFs are important for T~reg~ program and function, including T-bet, GATA3, Helios, and FoxA1 ([@R9]--[@R11]).

The *Foxp3* locus has several conserved noncoding sequences (CNS-0-3), each with specific roles in Foxp3 expression ([@R12]). CNS-0, located at a T~reg~ super-enhancer (SE), is needed to induce Foxp3 expression in T~reg~ cell precursors in a manner dependent on the genome organizer Satb1 ([@R13]). CNS-1 and CNS-2 are located in the intron following the untranslated exon 1 of the *Foxp3* gene, and CNS-3 is located in the intron after the first coding exon. CNS-1 is essential for induction of Foxp3 expression and generation of peripherally induced T~reg~ (pT~reg~) cells, especially in the intestine and lung ([@R12]). CNS-2 is bound by the RUNX1-Cbfβ complex, and its hypomethylation is needed for prolonged and stable expression of Foxp3 and T~reg~ stability ([@R14]). Its deletion results in loss of Foxp3 expression and unstable T~reg~ cells, which start secreting proinflammatory cytokines ([@R12]).

T~reg~ cells use several mechanisms to suppress aberrant immune responses. They constitutively express cytotoxic T-lymphocyte associated protein 4 (CTLA4), which provides an off signal and competes with CD28 on effector T (T~eff~) cells for interaction with B7 on dendritic cells and other antigen-presenting cells ([@R15]). CD25 is the high-affinity interleukin-2 (IL-2) receptor, which can leach IL-2 from the environment, depleting T~eff~ cells of the necessary IL-2 to survive. The triphosphate diphosphohydrolase 1 (*Entpd1*/CD39) is up-regulated on T~reg~ cells in inflammatory conditions and converts extracellular ATP (adenosine triphosphate) to ADP (adenosine diphosphate) and AMP (adenosine monophosphate), which are further metabolized into suppressive pericellular adenosine (pAde) by another ectonucleotidase, 5-nucleotidase-ecto (*Nt5e*/CD73). pAde binds to the A2A receptor on T~eff~ cells, and pAde/A2AAR signaling causes accumulation of cAMP (3′,5′-cyclical adenosine monophosphate) that blocks T~eff~ cell proliferation and production of proinflammatory cytokines. Glucocorticoid-induced tumor necrosis factor--related receptor (*Tnfrsf18*/GITR) is constitutively expressed on T~reg~ cells and has immunosuppressive effects \[reviewed in ([@R4])\].

Bcl11b is a C2H2 zinc finger DNA binding protein ([@R16], [@R17]), which functions as a transcriptional repressor when associated with the Nucleosome Remodeling and Deacetylase complex (Mi-2/NuRD) ([@R18]) and as a transcriptional activator when associated with histone acetyl transferases ([@R19]). Bcl11b is first expressed at the DN2 stage of thymocyte development and plays essential roles in thymocyte development, commitment, selection, and survival ([@R20]--[@R24]). In addition, Bcl11b is required for invariant natural killer T (iNKT) cell development by controlling the glycolipid processing and presentation by double-positive (DP) thymocytes and the functional program of iNKT cells ([@R25], [@R26]). Removal of Bcl11b from mature T cells leads to multiple defects including the derepression of the T helper 2 (T~H~2) program in T~H~17 cells ([@R27]) and failure of T~H~2 cells to differentiate during asthma and antihelminth responses ([@R28]). Absence of Bcl11b in innate lymphoid cells type 2 (ILC2) results in loss of their identity and derepression of the ILC3 program ([@R29]). CD8^+^ T cells fail to expand in an antigen-specific manner and have reduced effector function ([@R30], [@R31]). We previously reported that removal of Bcl11b with the CD4-Cre deleter or with the Foxp3--Cre--GFP (green fluorescent protein) BAC (bacterial artificial chromosome), which deletes slowly because of its reduced Cre levels, caused wasting disease associated with colitis and reduced formation of inducible T~reg~ cells and altered expression of Foxp3 and IL-10, as well as acquisition of proinflammatory genes ([@R32]). To investigate the molecular mechanisms by which Bcl11b controls T~reg~ cell programs, we used the Foxp3YFP-Cre strain with high expression of Cre and efficient removal of floxed alleles in T~reg~ cells ([@R33]). Bcl11b^F/F^ Foxp3YFP-Cre^+^ male mice and Bcl11b^F/F^ Foxp3YFP-Cre^+/+^ female mice \[Bcl11b/T~reg~ knockout (KO) mice\] died at an early age, presenting fatal systemic autoimmunity. Bcl11b-deficient T~reg~ cells showed altered suppression function even when isolated from mice with no inflammation due to the copresence of wild-type (WT) T~reg~ cells. In addition, Bcl11b-deficient T~reg~ cells showed reduced functional suppression molecules at steady state in inflammatory conditions and in tumors. Bcl11b bound at the upstream and intronic regions of several essential T~reg~ genes both in mice and humans, including at the *Foxp3* locus and at other T~reg~ genes, namely, *Ikzf2*, *Ctla4*, *Il2ra*, and *Tnfrsf18*. Binding of Bcl11b at many of these sites overlapped with Foxp3 binding in mouse T~reg~ cells, suggesting a synergistic role in the control of these genes. Absence of Bcl11b altered chromatin accessibility at these genes and their expression. Bcl11b also bound at the NK cell TF *Id2* locus, at several NK receptor loci, at *Spi1*, and other myeloid genes both in mouse and human T~reg~ cells, suggesting a direct and conserved control of their expression in T~reg~ cells. Thus, we demonstrate that Bcl11b is an essential TF for supporting T~reg~ cell program and restraining innate lineage programs in T~reg~ cells.

RESULTS
=======

Removal of Bcl11b in T~reg~ cells causes fatal systemic autoimmunity
--------------------------------------------------------------------

In the current study, we used the Foxp3YFP-Cre mice, which express yellow fluorescent protein (YFP)--Cre from the Foxp3 locus and have very efficient removal of Plox alleles only in T~reg~ cells ([@R33]). Bcl11b^F/F^ Foxp3YFP-Cre^+^ male mice and Bcl11b^F/F^ Foxp3YFP-Cre^+/+^ female mice (Bcl11b/T~reg~ KO mice) died between 20 and 40 days of age, with few exceptions living 60 days ([Fig. 1A](#F1){ref-type="fig"}), and showed reduced weight compared with sex-matched heterozygous (HT) littermates ([Fig. 1B](#F1){ref-type="fig"}). Bcl11b/T~reg~ KO mice showed enlarged peripheral lymphoid organs with disrupted architecture ([Fig. 1C](#F1){ref-type="fig"}). In addition, Bcl11b/T~reg~ KO mice developed eczematous dermatitis and blepharitis ([Fig. 1D](#F1){ref-type="fig"} and data not shown), similar to Scurfy mice, which are known to have a loss-of-function mutation in the *Foxp3* gene ([@R5]). Skin, lung, and other internal organs had massive infiltrations of leukocytes ([Fig. 1D](#F1){ref-type="fig"} and data not shown). Frequencies of CD8^+^ T cells in peripheral lymphoid organs of Bcl11b/T~reg~ KO mice were increased, while CD4^+^ T cells were variable ([Fig. 1E](#F1){ref-type="fig"} and data not shown). However, frequencies and absolute numbers of both CD44^+^CD4^+^ T and CD44^+^CD8^+^ T cells were significantly increased in Bcl11b/T~reg~ KO mice ([Fig. 1, F and G](#F1){ref-type="fig"}, and data not shown), which is indicative of an activated phenotype. The percentages and absolute numbers of T~reg~ cells in the peripheral lymph nodes (peLNs) and spleens of Bcl11b/T~reg~ KO mice showed a significant decrease compared with HT mice ([Fig. 1, H and I](#F1){ref-type="fig"}). Thus, Bcl11b/T~reg~ KO mice develop multiorgan fatal autoimmunity and lymphadenopathy with uncontrolled activation of T cells and a reduction in T~reg~ cell frequency.

![Bcl11b removal in T~reg~ cells results in early death of mice and increased CD4^+^ and CD8^+^ T cell activation.\
(**A**) Kaplan-Meier survival curves of mice with the following genotypes: Bcl11b^F/F^ Foxp3YFP-Cre^+^ (Bcl11b/T~reg~ KO) and Bcl11b^F/WT^ Foxp3YFP-Cre^+^ (HT) male and Bcl11b^F/F^ Foxp3YFP-Cre^+/+^ (Bcl11b/T~reg~ KO) and Bcl11b^F/WT^ Foxp3YFP-Cre^+/+^ (HT) female. (**B**) Matched weights of Bcl11b/T~reg~ KO and HT male littermates and female littermates at 3 to 4 weeks of age. (**C**) Peripheral lymph nodes (peLNs) and spleens of 3- to 4-week-old Bcl11b/T~reg~ KO and HT mice. Hematoxylin and eosin (H&E) staining showing the architecture of peLN and spleen. (**D**) H&E staining of skin and lung samples of 3- to 4-week-old Bcl11b/T~reg~ KO and HT mice. (**E**) Average frequencies of CD8^+^ T cells in peLNs and spleens of Bcl11b/T~reg~ KO and HT mice. (**F**) Representative CD44 histograms in CD4^+^ and CD8^+^ T cells from peLNs and spleens of Bcl11b/T~reg~ KO and HT mice. (**G**) Average frequencies of CD44^+^ CD4^+^ and CD44^+^ CD8^+^ T cells in peLNs and spleens of Bcl11b/T~reg~ KO and HT mice. (**H**) Representative flow plots of T~reg~ cells in Bcl11b/T~reg~ KO and HT mice isolated from peLNs and spleens. (**I**) Average frequencies of T~reg~ cells in Bcl11b/T~reg~ KO and HT mice (*n* = 7). Analysis was conducted on Bcl11b/T~reg~ KO and HT control mice. *P* values determined by Student's *t* test. \*\**P* \< 0.01, \*\*\**P* \< 0.001, \*\*\*\**P* \< 0.0001. Photo credit: Mohammad Uddin, University of Florida.](aaw0480-F1){#F1}

Bcl11b deletion causes a decrease in key T~reg~ markers
-------------------------------------------------------

Given that Bcl11b/T~reg~ KO mice showed multiorgan inflammation, we made use of Bcl11b^F/F^ Foxp3YFP-Cre^+/−^ mosaic female mice (Bcl11b/T~reg~ KO mosaic female mice), which, in addition to YFP^+^Bcl11b KO T~reg~ cells, have YFP^−^ WT T~reg~ cells as a result of random inactivation of X chromosome--linked genes. We found that Bcl11b/T~reg~ KO mosaic female mice did not develop overt signs of autoimmunity and weight loss. However, YFP^+^ T~reg~ cells of Bcl11b/T~reg~ KO mosaic female mice showed decreased frequencies and mean fluorescence intensities (MFIs) of CD25, CTLA4, and GITR when compared with YFP^−^ T~reg~ cells from the same mouse ([Fig. 2, A to F](#F2){ref-type="fig"}). In addition, frequency of Helios^+^ T~reg~ cells and MFI were both significantly decreased in Bcl11b KO T~reg~ cells of Bcl11b/T~reg~ KO mosaic female mice compared with YFP^−^ WT T~reg~ cells ([Fig. 2, G and H](#F2){ref-type="fig"}). Furthermore, frequency and absolute numbers of YFP^+^ T~reg~ cells in the Bcl11b/T~reg~ KO mosaic female mice were decreased compared with corresponding YFP^+^ T~reg~ cells in the Bcl11b^F/WT^ Foxp3YFP-Cre^+/−^ HT mosaic female mice ([Fig. 2, I and J](#F2){ref-type="fig"}), and the MFIs for YFP and Foxp3 were also diminished in the absence of Bcl11b ([Fig. 2K](#F2){ref-type="fig"}). Thus, while the YFP^−^ WT T~reg~ cells can prevent autoimmunity in the Bcl11b/T~reg~ KO mosaic female mice, many key T~reg~ cell markers are dysregulated in the absence of Bcl11b at steady state in YFP^+^ Bcl11b KO T~reg~ cells.

![Bcl11b-deficient T~reg~ cells of Bcl11b/T~reg~ KO mosaic female mice have decreased suppression markers at steady state.\
(**A**, **C**, and **E**) Representative histograms and average frequencies of CD25^+^ (A), CTLA4^+^ (C), and GITR^+^ (E) YFP^+^Foxp3^+^ (KO) and YFP^−^Foxp3^+^ (WT) T~reg~ cells within the same Bcl11b^F/F^ Foxp3YFP-Cre^+/−^ (Bcl11b/T~reg~ KO mosaic) female mice. (**B**, **D**, and **F**) Mean fluorescence intensities (MFIs) of surface CD25 (B), CTLA4 (D), and GITR (F) on YFP^+^Foxp3^+^ (KO) and YFP^−^Foxp3^+^ (WT) T~reg~ cells of Bcl11b/T~reg~ KO mosaic female mice at steady state (*n* = 6). (**G**) Representative histogram and average frequencies of Helios in YFP^+^Foxp3^+^ (KO) and YFP^−^Foxp3^+^ (WT) T~reg~ cells from peLNs of Bcl11b/T~reg~ KO mosaic female mice at steady state. (**H**) MFI of Helios in YFP^+^Foxp3^+^ (KO) and YFP^−^Foxp3^+^ (WT) T~reg~ cells from peLNs of Bcl11b/T~reg~ KO mosaic female mice (*n* = 4). Analysis was conducted on YFP^+^Foxp3^+^ (KO) and YFP^−^Foxp3^+^ (WT) T~reg~ cells of Bcl11b/T~reg~ KO mosaic female mice (A to H). (**I**) Representative contour plots depicting the YFP^+^Foxp3^+^ (KO) and YFP^−^Foxp3^+^ (WT) T~reg~ cells in Bcl11b^F/F^Foxp3YFP-Cre^+/−^ (Bcl11b/T~reg~ KO mosaic) and Bcl11b^F/WT^ Foxp3YFP-Cre^+/−^ (HT mosaic) female mice. (**J**) Frequencies and absolute numbers of YFP^+^ T~reg~ cells in Bcl11b/T~reg~ KO mosaic and HT mosaic female mice. (**K**) Foxp3 and YFP MFIs in YFP^+^Foxp3^+^ T~reg~ cells from Bcl11b/T~reg~ KO mosaic and HT mosaic female mice (*n* = 7). Analysis was conducted on YFP^+^ T~reg~ cells from Bcl11b/T~reg~ KO mosaic and HT mosaic female mice (J and K). *P* values determined by Student's *t* test. \**P* \< 0.05, \*\**P* \< 0.01, \*\*\**P* \< 0.001, \*\*\*\**P* \< 0.0001.](aaw0480-F2){#F2}

Functional markers remain decreased in Bcl11b-deficient T~reg~ cells in inflammation and tumors
-----------------------------------------------------------------------------------------------

We further evaluated functional markers in Bcl11b KO YFP^+^ and WT YFP^−^ T~reg~ cells of Bcl11b/T~reg~ KO mosaic female mice induced with experimental autoimmune encephalomyelitis (EAE) to determine their status in inflammatory conditions. Frequencies of CD25^+^, CTLA4^+^, and GITR^+^ T~reg~ cells, as well as their MFIs, remained reduced during EAE in Bcl11b KO YFP^+^ T~reg~ cells compared with WT T~reg~ cells ([Fig. 3, A to F](#F3){ref-type="fig"}, and table S1). In addition, there was a major reduction in the CD39^+^CD73^+^ T~reg~ cell population in the absence of Bcl11b in EAE conditions ([Fig. 3G](#F3){ref-type="fig"} and table S1). Of note, CD39^+^CD73^+^ T~reg~ cell frequency and their MFIs are low at steady state even in WT T~reg~ cells.

![T~reg~ cell markers and suppression function are altered in the absence of Bcl11b during inflammation.\
(**A**, **C**, and **E**) Representative histograms and average frequencies of CD25 (A), CTLA4 (C), and GITR (E) in YFP^+^Foxp3^+^ (KO) and YFP^−^Foxp3^+^ (WT) T~reg~ cells of Bcl11b^F/F^ Foxp3YFP-Cre^+/−^ (Bcl11b/T~reg~ KO mosaic) female mice induced with EAE. dLN, draining lymph node. (**B**, **D**, and **F**) MFI of CD25 (B), CTLA4 (D), and GITR (F) in YFP^+^Foxp3^+^ (KO) and YFP^−^Foxp3^+^ (WT) T~reg~ cells of Bcl11b/T~reg~ KO mosaic female mice induced with EAE. (**G**) Representative contour plots of CD39, CD73, and average frequencies of CD39^+^CD73^+^ YFP^+^Foxp3^+^ (KO) and YFP^−^Foxp3^+^ (WT) T~reg~ cells of Bcl11b/T~reg~ KO mosaic female mice induced with EAE (*n* = 16). Analysis was conducted on YFP^+^Foxp3^+^ (KO) and YFP^−^Foxp3^+^ (WT) T~reg~ cells of Bcl11b/T~reg~ KO mosaic female (A to G). (**H** and **I**) Rag1^−/−^ mice transferred with 4 × 10^5^ CD45RB^hi^ CD4^+^ T cells from CD45.1 WT mice to induce colitis and either 1 × 10^5^ YFP^+^ T~reg~ cells from Bcl11b/T~reg~ KO mosaic female mice (CD45.2) (red), or from HT mosaic female mice (black) (CD45.2), or no T~reg~ cells (blue). (H) Average weight loss/gain of Rag1^−/−^ mice transferred as indicated above (*n* = 10). (I) Histopathological scores of Rag1^−/−^ mice transferred as indicated above. Analysis was conducted on Rag1^−/−^ mice transferred as indicated above. *P* values determined by Student's *t* test. \**P* \< 0.05, \*\**P* \< 0.01, \*\*\**P* \< 0.001, \*\*\*\**P* \< 0.0001. n.s., not significant.](aaw0480-F3){#F3}

We further induced flank tumors in Bcl11b/T~reg~ KO mosaic and HT mosaic control female mice with B16-Ova melanoma, and as expected, the tumor sizes were not different between the two groups, likely due to the presence of WT YFP^−^ cells even in Bcl11b/T~reg~ KO mosaic female mice. We then evaluated the phenotype of Bcl11b KO YFP^+^ and WT YFP^−^ T~reg~ cells in Bcl11b/T~reg~ KO mosaic female mice transplanted with B16-Ova flank tumors and found that similar to steady state and EAE conditions, Bcl11b KO YFP^+^ T~reg~ cells had reduced suppressive markers compared with the WT YFP^−^ T~reg~ cells in the same mouse. This included decreased levels and frequencies of CD25, CTLA4, GITR, CD39, and CD73 (fig. S1, A to H, and table S1). A comparison of the suppression markers in T~reg~ cells in inflammatory conditions (EAE), tumors, and steady state shows an overall decrease of these markers in the absence of Bcl11b in all three conditions. Among these markers, GITR, CD39, and CD73 showed even more decline in inflammatory conditions \[[Fig. 3 (A to G)](#F3){ref-type="fig"}, fig. S1 (A to H), and table S1\].

These results, thus, demonstrate that Bcl11b KO T~reg~ cells have alterations in essential T~reg~ functional markers at steady state, in inflammatory conditions, and in tumors, and some are further exacerbated in inflammatory conditions.

Bcl11b KO T~reg~ cells failed to control CD45Rb^hi^ CD4^+^ T cell--induced colitis
----------------------------------------------------------------------------------

Given the alterations in key T~reg~ markers in the absence of Bcl11b, we next evaluated the in vivo suppression ability of YFP^+^ T~reg~ cells derived from Bcl11b/T~reg~ KO mosaic female mice and control mosaic female mice in the colitis model of CD45Rb^hi^ CD4^+^ T cell transfer in immunodeficient mice ([@R34]). Naïve CD45Rb^hi^ CD4^+^ T cells were transferred into Rag1^−/−^ mice, provided also with YFP^+^ T~reg~ cells from Bcl11b/T~reg~ KO mosaic female mice or control HT mosaic female mice or with no other cells. While HT T~reg~ cells suppressed the weight loss of Rag1^−/−^ mice transferred with naïve CD4^+^ T cells, Bcl11b KO T~reg~ cells failed ([Fig. 3H](#F3){ref-type="fig"}). Histopathological analysis showed that mice transferred with naïve CD4^+^ T cells plus HT T~reg~ cells had significantly lower scores compared with those transferred with naïve CD4^+^ T cells only or with naïve CD4^+^ T cells plus Bcl11b KO T~reg~ cells ([Fig. 3I](#F3){ref-type="fig"}). Transferred Bcl11b KO T~reg~ cells were detectable at frequencies similar to that of HT T~reg~ cells at the completion of the study, with a slight, but not significant, decrease in the Foxp3^+^ cell frequency (fig. S2, A to C). These results demonstrate that deletion of Bcl11b in T~reg~ cells hampers their ability to suppress CD4^+^ T cell--mediated inflammation.

Bcl11b controls expression of essential T~reg~ program genes
------------------------------------------------------------

To establish the mechanistic basis for the functional failure of Bcl11b KO T~reg~ cells, we conducted RNA sequencing (RNA-seq) analysis of Bcl11b KO and WT YFP^+^ T~reg~ cells from Bcl11b/T~reg~ KO and WT mosaic female mice. Gene Set Enrichment Analysis (GSEA) showed that T~reg~ signature genes ([@R3]) were enriched in WT compared with Bcl11b KO T~reg~ cells in the absence of inflammation ([Fig. 4A](#F4){ref-type="fig"}). Within this signature, the mRNA for *Foxp3* was significantly reduced ([Fig. 4B](#F4){ref-type="fig"}), as was for Helios (*Ikzf2*) ([Fig. 4B](#F4){ref-type="fig"}), encoding a TF controlling stability of T~reg~ cells and characteristic of thymically derived T~reg~ cells ([@R11]). In addition, T~reg~ genes belonging to the functional program, including *Ctla4*, CD25 (*Il2ra*), *Gitr*, and *Nt5e* (CD73), were down-regulated ([Fig. 4B](#F4){ref-type="fig"}). Of note, protein levels of these markers were also decreased ([Fig. 2](#F2){ref-type="fig"}).

![Bcl11b regulates expression of key T~reg~ cell genes while suppressing inflammatory and innate genes.\
(**A**) GSEA showing enrichment of T~reg~ signature genes in WT T~reg~ cells (*n* = 2) compared with Bcl11b KO T~reg~ cells (*n* = 2). RNA-seq was conducted on T~reg~ cells sorted from Bcl11b/T~reg~ KO mosaic and WT female mice. NES, normalized enrichment score. (**B**) Graphs showing normalized read counts of key T~reg~ genes from RNA-seq of Bcl11b KO and WT T~reg~ cells (*n* = 2). (**C**) GSEA plots showing enrichment of inflammatory and allograft rejection pathways in Bcl11b KO T~reg~ cells versus WT (*n* = 2). (**D**) Heatmap of normalized read counts of myeloid and NK cell program genes from RNA-seq of Bcl11b KO and WT T~reg~ cells (*n* = 2). (**E**) Graphs showing normalized read counts of selected myeloid and NK cell genes (*n* = 2). (**F**) Distribution of fold changes of differentially expressed (DE) genes between Bcl11b KO and WT T~reg~ cells at steady state and in EAE. FC, fold change. (**G**) Venn diagram of the proportion of unique and shared differentially expressed genes between Bcl11b KO and WT T~reg~ cells at steady state and in EAE. (**H**) Scatter plot of RNA-seq log~2~ (fold change) of the T~reg~ signature genes at steady state and in EAE. False discovery rate (FDR)--adjusted *P* values were calculated using the Benjamini-Hochberg method, with a significance cutoff of adjusted *P* \< 0.05.](aaw0480-F4){#F4}

Bcl11b represses a proinflammatory gene signature in T~reg~ cells
-----------------------------------------------------------------

In addition, Bcl11b KO T~reg~ cells displayed enhanced inflammatory and allograft rejection gene signatures ([Fig. 4C](#F4){ref-type="fig"}), which included up-regulation of genes such as *Ifng*, *Il15*, *Il18*, *Il2*, and *Il1b* (fig. S3, A and B). Thus, Bcl11b represses proinflammatory genes in T~reg~ cells.

Bcl11b globally represses expression of myeloid and NK genes in T~reg~ cells
----------------------------------------------------------------------------

Further analysis of the RNA-seq data shows that the absence of Bcl11b resulted in up-regulation of mRNAs for multiple myeloid and NK genes in T~reg~ cells ([Fig. 4, D and E](#F4){ref-type="fig"}). Specifically, the mRNAs for the critical TFs for NK and myeloid lineages, ID2 and PU.1, respectively, were both up-regulated in the absence of Bcl11b ([Fig. 4, D and E](#F4){ref-type="fig"}). From the NK program, several killer cell lectin-like receptor genes, including *Klrb1b*, *Klrb1c* (encoding Nk1.1), *Klrk1* (encoding Nkg2d), *Klrd1*, and *Cd160*, were all up-regulated ([Fig. 4, D and E](#F4){ref-type="fig"}). From the myeloid program, *Fcer1g*, *Fcgr3*, *Cd14*, *Cd74*, *Itgb3*, and *Itgad* were up-regulated ([Fig. 4, D and E](#F4){ref-type="fig"}). In addition, genes with role in hematopoiesis, such as *c-kit* and *Cd9*, were up-regulated ([Fig. 4D](#F4){ref-type="fig"}). These results point to a critical role of Bcl11b in repressing expression of NK and myeloid cell programs in T~reg~ cells.

Bcl11b controls the same genes in inflammation and at steady state
------------------------------------------------------------------

We next conducted RNA-seq in WT and Bcl11b KO T~reg~ cells isolated from EAE mice to identify commonly or uniquely controlled genes by Bcl11b in inflammation versus steady state. More genes were differentially expressed between KO and WT T~reg~ cells during steady state than in EAE ([Fig. 4F](#F4){ref-type="fig"}). However, during both EAE and steady state, more genes were up-regulated than down-regulated, and most up-regulated genes displayed a higher fold change ([Fig. 4F](#F4){ref-type="fig"}). Most genes were commonly differentially expressed at SS and in EAE, suggesting that Bcl11b controls similar programs in the presence or absence of inflammation in T~reg~ cells ([Fig. 4G](#F4){ref-type="fig"}). A significant correlation of differentially expressed genes in the T~reg~ gene signature, allograft rejection, and inflammatory response pathways was observed at steady state and in EAE ([Fig. 4H](#F4){ref-type="fig"} and fig. S3, A and B).

Bcl11b predominantly binds to intergenic and intronic regions in T~reg~ cells
-----------------------------------------------------------------------------

We further performed Bcl11b chromatin immunoprecipitation sequencing (ChIP-seq) analysis on T~reg~ cells to identify genes directly controlled by Bcl11b, which we compared with Bcl11b genomic binding in naïve CD4^+^ T cells ([@R28]). Given that numerous genes regulated by Bcl11b are also known Foxp3 targets, we also compared the genomic binding by Bcl11b with Foxp3 binding in T~reg~ cells ([@R35]). Peak annotation showed that Bcl11b predominantly bound to intergenic and intronic regions and less to promoter regions in T~reg~ cells ([Fig. 5A](#F5){ref-type="fig"}), similarly to conventional CD4^+^ T cells ([@R28]). In line with our previous observations in conventional CD4^+^ T cells ([@R28]), motif analysis showed that the top 2 motifs were ETS (E26 transformation-specific) and Runx (Runt-related transcription factor) (fig. S4). Further motif analysis of peaks at up-regulated or down-regulated genes at steady state showed a significant overlap between motifs, as 7 of the top 10 motifs were present in both up-regulated and down-regulated gene sets (table S2). However, when comparing the relative enrichment of the top 10 motifs, the top 4 motifs for the down-regulated gene set were significantly enriched, and all constituted ETS-binding motifs (table S2), suggesting that Bcl11b may preferentially bind to ETS motifs to sustain gene expression. To establish whether Bcl11b controls the T~reg~ program in humans in a similar manner to mice, we performed Bcl11b ChIP-seq on sorted CD127^lo^CD25^hi^ CD4^+^ T~reg~ cells from human peripheral blood mononuclear cells (PBMCs). Motif analysis indicated that, similar to mouse T~reg~ cells, in human T~reg~ cells, the two most enriched motifs were for ETS and Runx (fig. S4).

![Bcl11b binds at key T~reg~ genes in mice and human T~reg~ cells and controls chromatin accessibility.\
(**A**) Peak annotation of Bcl11b-binding sites in T~reg~ cells in mice. (**B**) Integrative Genomics Viewer (IGV) visualization at the *Foxp3* locus of Foxp3 ChIP-seq in T~reg~ cells (track 1) ([@R35]), Bcl11b ChIP-seq in mouse T~reg~ cells (track 2), naïve CD4^+^ T cells (track 3), and Bcl11b ChIP-seq in human T~reg~ cells (track 4). (**C** and **D**) IGV visualization of mouse Foxp3 ChIP-seq in T~reg~ cells (track 1) ([@R35]), Bcl11b ChIP-seq in T~reg~ cells (track 2), naïve CD4^+^ T cells (track 3), ATAC-seq (tracks 4 and 5) in T~reg~ cells from Bcl11b^F/F^Foxp3YFP-Cre^+/−^ (Bcl11b/T~reg~ KO mosaic) and Bcl11b^F/WT^ Foxp3YFP-Cre^+/−^ HT mosaic female mice, and Bcl11b ChIP-seq in human T~reg~ cells (track 6) at *Ikzf2* (Helios) (C), and *Il2ra* (CD25), *Ctla4*, and *Tnfrsf18* (GITR) (D). Blue highlights indicate statistically significant DA ATAC-seq peaks. Gray highlights indicate significant ChIP-seq peaks. ChIP-seq and ATAC-seq track scale bar normalized to sequences per million reads. (**E**) Venn diagram of Bcl11b ChIP-seq peaks from T~reg~ and naïve CD4^+^ T cells ([@R28]) at T~reg~ signature genes. (**F**) Peak annotation of differentially accessible ATAC-seq peaks between T~reg~ cells of Bcl11b/T~reg~ KO mosaic and HT mosaic female mice. (**G**) Metacoverage plot from HOMER of differentially accessible ATAC-seq peaks annotated to T~reg~ signature genes in T~reg~ cells from Bcl11b/T~reg~ KO mosaic and HT mosaic females (left) and naïve Bcl11b KO and WT CD4^+^ T cells (right) ([@R28]). TTS, transcription termination site.](aaw0480-F5){#F5}

Bcl11b binds at *Foxp3* CNS-0 and CNS-2 in mouse and human T~reg~ cells
-----------------------------------------------------------------------

We then evaluated binding of Bcl11b at the *Foxp3* locus in mouse and human T~reg~ cells. *Foxp3* CNSs are conserved between mice and humans ([@R12]), and CNS-2 is hypomethylated in human T~reg~ cells, similar to CNS-2 in mouse T~reg~ cells, suggesting a common mechanism of regulation of Foxp3 expression in mice and humans. Bcl11b bound at CNS-0 ([Fig. 5B](#F5){ref-type="fig"}), a site located in a T~reg~ SE and bound by the pioneer factor Satb1, which initiates Foxp3 expression by facilitating chromatin accessibility at the *Foxp3* gene locus ([@R13]). In addition, Bcl11b bound at CNS-2 both in mouse and human T~reg~ cells ([Fig. 5B](#F5){ref-type="fig"}), confirming our previous observations by ChIP--quantitative polymerase chain reaction ([@R32]). Although not needed for Foxp3 induction, CNS-2 is required for continuous expression of Foxp3 in T~reg~ cells ([@R12]). In addition, we found that, in mouse CD4^+^ T cells, Bcl11b bound at CNS-0, but not at CNS-2, supporting the idea that CNS-2 binding by Bcl11b is specific to T~reg~ cells ([Fig. 5B](#F5){ref-type="fig"}). The binding to CNS-2 and CNS-0 coincided with Foxp3 binding ([@R35]). Thus, Bcl11b likely promotes the continued maintenance of Foxp3 expression in human and mouse T~reg~ cells through binding at CNS-2. This is in agreement with the reduction in *Foxp3* mRNA and protein in murine Bcl11b-deficient T~reg~ cells. Bcl11b may also act early to initiate Foxp3 expression through CNS-0.

Bcl11b binds at T~reg~ program genes at common sites with Foxp3
---------------------------------------------------------------

Analysis of Bcl11b and Foxp3 binding at T~reg~ signature genes showed that Bcl11b had overlapping binding with Foxp3 at approximately 50% of all the genes in the T~reg~ gene signature, and many of those genes showed similar changes at the RNA level in Bcl11b-deficient T~reg~ cells during steady state and in EAE (table S3). Given these results, we performed a proximity ligation assay (PLA) to determine whether Bcl11b and Foxp3 interact. We found that Bcl11b and Foxp3 interact, at least, in a subset of T~reg~ cells (fig. S5), further supporting the previous finding that Foxp3 and Bcl11b were present in the same complex ([@R8]). Therefore, it is likely that Bcl11b and Foxp3 act cooperatively to regulate the expression of many T~reg~ signature genes. In this line, Bcl11b bound at the promoter, an intronic region, as well as at an upstream location of the *Ikzf2* (Helios) locus, in a recently identified T~reg~ SE ([Fig. 5C](#F5){ref-type="fig"} and fig. S6A) ([@R13]), and the peaks corresponded to regions bound by Foxp3 ([Fig. 5C](#F5){ref-type="fig"} and data not shown). *Ikzf2* mRNA and protein were reduced in Bcl11b KO T~reg~ cells \[[Figs. 2 (G and H)](#F2){ref-type="fig"} and [4B](#F4){ref-type="fig"}). Genes involved in T~reg~ cell--mediated suppression function bound by Bcl11b included *Ctla4*, *Il2ra*, and *Tnfrsf18* (GITR) ([Fig. 5D](#F5){ref-type="fig"}), which were all down-regulated at the mRNA and protein levels in Bcl11b KO T~reg~ cells \[[Figs. 2 (A to F)](#F2){ref-type="fig"}, [3 (A to F)](#F3){ref-type="fig"}, and [4B](#F4){ref-type="fig"}\]. Bcl11b binding occurred at the same location as Foxp3 at these T~reg~ signature genes, some in the promoters, the introns, or the vicinity of the gene ([Fig. 5D](#F5){ref-type="fig"}). The binding sites at *Il2ra* and *Ctla4* were in a recently identified T~reg~ SE (fig. S6, B and C) ([@R13]). Unexpectedly, Bcl11b also bound many of the T~reg~-specific genes in naïve CD4^+^ T cells ([Fig. 5, C to E](#F5){ref-type="fig"}). These results demonstrate that Bcl11b regulates the T~reg~ gene program by directly binding to the regulatory regions of T~reg~ genes, and many times, the binding sites overlap with Foxp3 binding, suggesting that Bcl11b cooperates with Foxp3 in supporting expression of signature T~reg~ genes.

Bcl11b binds at the same T~reg~ signature genes in humans as in mice
--------------------------------------------------------------------

In addition to conserved binding at the *Foxp3* locus in humans and mice, Bcl11b bound at the same key T~reg~ signature genes in human T~reg~ cells as in mice ([Fig. 5, C and D](#F5){ref-type="fig"}). Specifically, Bcl11b bound at the *IKZF2* promoter and intronic regions ([Fig. 5C](#F5){ref-type="fig"}), the *IL2RA* promoter and intronic regions, the *CTLA4* intronic regions as well as a regulatory region upstream of the promoter, and at potential regulatory regions near the gene body of *TNFRSF18* (GITR) ([Fig. 5D](#F5){ref-type="fig"}). These results demonstrate that many of the same key T~reg~ signature genes that were bound and regulated by Bcl11b in mice were also bound in human T~reg~ cells, suggesting a conserved regulatory mechanism exerted by Bcl11b in human and mouse T~reg~ cells.

Bcl11b maintains chromatin accessibility at T~reg~ signature genes only in T~reg~ cells
---------------------------------------------------------------------------------------

We performed assay for transposase-accessible chromatin sequencing (ATAC-seq) ([@R36]) on YFP^+^ Bcl11b KO and HT T~reg~ cells to determine the global changes in chromatin accessibility dependent on Bcl11b. We found that most of the changes in chromatin accessibility occurred in the intergenic and intronic regions ([Fig. 5F](#F5){ref-type="fig"}), similar to the distribution of Bcl11b-bound regions. A total of 39,031 differentially accessible peaks were identified, of which approximately half (19,816) were less accessible in the KO T~reg~ cells. We then compared chromatin accessibility at T~reg~ signature genes bound by Bcl11b in Bcl11b KO and HT T~reg~ cells, as well as in Bcl11b KO and WT naïve CD4^+^ T cells. Chromatin accessibility was reduced in Bcl11b KO T~reg~ cells, but not in Bcl11b KO CD4^+^ T cells ([Fig. 5G](#F5){ref-type="fig"}), despite the fact that Bcl11b bound in naïve CD4^+^ T cells at many of these T~reg~ signature genes. From the T~reg~-specific genes, *Ctla4*, *Il2ra*, and *Tnfrsf18* all had reduced chromatin accessibility in the absence of Bcl11b in T~reg~ cells ([Fig. 5D](#F5){ref-type="fig"}). These results demonstrate that Bcl11b binds essential T~reg~ signature genes and controls their chromatin accessibility in T~reg~ cells. However, even if Bcl11b binds many of the same T~reg~ signature genes in naïve CD4^+^ T cells, Bcl11b is unable to regulate the chromatin accessibility at those genes in naïve CD4^+^ T cells.

Bcl11b binds at myeloid TF genes in mouse and human T~reg~ cells
----------------------------------------------------------------

Since myeloid genes were significantly up-regulated in the absence of Bcl11b, we sought to determine whether Bcl11b directly bound these genes to repress their expression. We found binding by Bcl11b at two regions upstream of the myeloid lineage TF *Spi1* (PU.1) ([Fig. 6A](#F6){ref-type="fig"}) ([@R37]), as well as at the promoter region of *Cebpa,* which encodes a critical TF for myeloid lineage priming and granulocyte development ([Fig. 6A](#F6){ref-type="fig"}) ([@R38]). This is similar to Bcl11b binding in naïve CD4^+^ T cells and in T~H~2 cells during helminth infection ([@R28]). In addition, in human T~reg~ cells, we identified two Bcl11b-binding sites upstream of *SPI1*, as well as binding at the promoter region of *CEBPA* ([Fig. 6A](#F6){ref-type="fig"}), suggesting that Bcl11b may similarly regulate these critical lineage defining TFs in humans and mice.

![Bcl11b binds at NK and myeloid genes in mouse and human T~reg~ cells.\
(**A** and **B**) IGV visualization of Bcl11b ChIP-seq in mouse T~reg~ cells (track 1) and human T~reg~ cells (track 2) at *Spi1* and *Cebpa* (A), *Id2*, *Klrb1c*, and *Klrb1b* (B). Gray highlights indicate significant ChIP-seq peaks. ChIP-seq scale bar normalized to sequences per million reads. bp, base pairs.](aaw0480-F6){#F6}

Bcl11b binds at the NK gene complex and *Id2* in mouse and human T~reg~ cells
-----------------------------------------------------------------------------

Given the up-regulation of NK cell mRNAs, we next examined Bcl11b binding at NK genes in T~reg~ cells. Bcl11b was recently shown to block the NK cell program in developing T cells by binding and repressing *Id2* expression ([@R39]), which is critical for NK cell development. We found that Bcl11b bound both in mouse T~reg~ cells and naïve CD4^+^ T cells at the *Id2* promoter, as well as at a 5′ upstream location ([Fig. 6B](#F6){ref-type="fig"} and data not shown). Similarly in human T~reg~ cells, Bcl11b bound at the *ID2* promoter and at multiple regions downstream of the *ID2* locus ([Fig. 6B](#F6){ref-type="fig"}). In addition, Bcl11b bound at several regions within the murine NK gene complex in T~reg~ cells, more remarkably at two regions located between *Klrb1b* and *Klrb1c* loci and at two other regions upstream of *Klrb1b* ([Fig. 6B](#F6){ref-type="fig"}). Furthermore, Bcl11b bound at an upstream location of *KLRB1* ([Fig. 6B](#F6){ref-type="fig"}), suggesting conserved binding of potential regulatory elements despite the divergence of the NK gene complex between mice and humans. These results suggest that Bcl11b blocks NK lineage programs in T~reg~ cells in mice and humans not only through control of *Id2* expression but also through direct control of NK gene complex expression.

DISCUSSION
==========

The TF Foxp3 is a hallmark of T~reg~ cells; however, Foxp3 is not sufficient to control the T~reg~ program alone, and other TFs are important in this regard. This study demonstrates the fundamental role of Bcl11b in regulating the T~reg~ signature program while repressing the innate lineage programs in mouse T~reg~ cells. In the absence of Bcl11b, T~reg~ cells were unable to exert their suppression function, which led to the inability to control multiorgan inflammation. Even when isolated from Bcl11b/T~reg~ KO mosaic female mice, in the absence of inflammation, Bcl11b KO T~reg~ cells failed to control CD45Rb^hi^ CD4^+^ T cell--induced colitis in Rag1^−/−^ mice. This failure was likely due to reduced levels of critical T~reg~ suppression genes, including *Il2ra*, *Ctla4*, *Nt5e*, and *Gitr.* Mechanistic studies using genome-wide binding analysis of Bcl11b show that Bcl11b directly regulates the expression of many of these genes by binding to genomic regulatory regions, both in mouse and human T~reg~ cells, thus making Bcl11b an essential TF for the T~reg~ program both in mice and humans. All the key T~reg~ signature genes bound and regulated by Bcl11b in mouse T~reg~ cells, including *Foxp3*, *Ikzf2*, *Il2ra*, *Ctla4*, and *Tnfrsf18*, were also bound by Bcl11b in human T~reg~ cells. In addition, the top two Bcl11b DNA binding motifs were shared between mouse and human T~reg~ cells, suggesting that our findings on the function of Bcl11b in mice correlate highly with its function in humans.

The absence of Bcl11b caused alterations in chromatin accessibility at these genes and reduction of their expression both at the mRNA and protein levels, resulting in a failure to suppress. We found that binding of Bcl11b at the T~reg~ signature genes overlapped with Foxp3 binding, suggesting a likely cooperative mechanism of action, supported by the observation that, at least, in a subpopulation of T~reg~ cells, Bcl11b and Foxp3 are in proximity. Intriguingly, Bcl11b also bound the majority of the same T~reg~ signature genes in mouse naïve CD4^+^ T cells, however without affecting chromatin accessibility at these genes in naive CD4^+^ T~reg~ cells. Thus, Bcl11b is likely poised at certain genomic sites waiting for Foxp3 and other TFs to cooperate in promoting expression of T~reg~ signature genes. The binding of Bcl11b at the same sites in CD4^+^ T cells as in T~reg~ cells also supports the idea that Bcl11b may play differential roles in the regulation of these genes in T~reg~ cells, where it may act in concert with Foxp3 to positively regulate their expression, and in contrast to CD4^+^ T cells, where Foxp3 is absent, and thus, Bcl11b may repress their expression. These results again underscore the complex and differential role of Bcl11b not only at different stages of T cell development but also at different subsets of T cells, depending on the T cell subset--specific TFs. Its role in T~reg~ cells in the regulation of T~reg~ signature program together with Foxp3 is one of these context-specific roles of Bcl11b. This specific role of Bcl11b contrasts with the general role of Bcl11b in both developing and mature T cells in directly repressing NK and myeloid cell TFs, such as *Id2* and *Spi1* (PU.1), respectively, and additionally directly repressing genes residing within the NK gene complex. Genome-wide analysis of BCL11B binding in human T~reg~ cells suggests conserved modalities of functioning and program regulation between humans and mice.

Unbiased ChIP-seq analysis revealed that Bcl11b bound at *Foxp3*'s CNS-2 both in mouse and human T~reg~ cells, required for sustained expression of Foxp3 in dividing T~reg~ cells. As shown in this study, even in an environment devoid of inflammation, in the absence of Bcl11b, T~reg~ cells cannot maintain Foxp3 expression in the periphery. Given that other TFs have been shown to bind to CNS-2, such as GATA3 ([@R10]) and the RUNX1-Cbfβ complex ([@R14]), the precise mechanism of sustaining Foxp3 expression remains to be elucidated. Bcl11b was also found to bind CNS-0, located in a T~reg~ SE and critical for induction of Foxp3 expression in the thymus ([@R13]), suggesting the possibility that Bcl11b may play a role in the induction of Foxp3 expression in early T~reg~ precursors by cooperating with Satb1, given that Bcl11b is also expressed in DP thymocytes. The pioneer factor Satb1 plays dual roles in regulating Foxp3 expression through binding at CNS-0. In the thymus, Satb1 is critical for initiating Foxp3 expression, while it represses the induction of Foxp3 expression during the generation of pT~reg~ cells ([@R13]). Intriguingly, we found that Bcl11b bound at CNS-0 both in naïve CD4^+^ T cells and in T~reg~ cells. Given our previous report that Bcl11b-deficient conventional CD4^+^ T cells less efficiently generated induced T~reg~ cells in vitro, we speculate that in naïve CD4^+^ T cells, Bcl11b may act in opposing Satb1's activity, thus promoting Foxp3 induction in conventional CD4^+^ T cells through its activity at CNS-0. This exemplifies not only the context-dependent activity of Bcl11b but also how Bcl11b can act differently with the same factor, in this case Satb1.

Bcl11b was shown to suppress myeloid and NK lineage programs early during T cell development ([@R21], [@R24]). However, it has become obvious that persistent expression of Bcl11b in the late stages of development and further in mature CD4^+^ and CD8^+^ T cells, as well as other T cell lineages, is required for repression of those innate cell programs ([@R20], [@R28]). We demonstrate here that Bcl11b is critical for repressing NK cell genes in T~reg~ cells not only by repressing *Id2* but also by directly repressing NK receptor genes, similarly to CD4^+^ T cells ([@R28]). It is likely that repression of the myeloid cell program by Bcl11b is through control of PU.1 and *Cebpa.* We found that all these genes are bound by Bcl11b in both mice and humans, providing evidence that Bcl11b's function in repressing the NK cell and myeloid cell lineages is conserved between mice and humans.

Bcl11b KO T~reg~ cells also showed reduced suppressive markers in conditions of inflammation, namely, in EAE, as well as in the context of tumors. Thus, it is plausible that ablation of Bcl11b would likely generate weakened T~reg~ cells, which may acquire NK receptors and potentially gain the ability to target tumor cells instead of sustaining a tumor-suppressing microenvironment. However, in the context of autoimmunity, expression of Bcl11b needs to be maintained in T~reg~ cells to promote their suppression program. Thus, Bcl11b may be an attractive target for cancer immunotherapies, but careful consideration will be required, given its role in maintaining T~reg~ cell suppression program in autoimmunity.

MATERIALS AND METHODS
=====================

Mice
----

Mice were bred under specific pathogen--free conditions and kept in-house for experiments in individually ventilated cages under specific pathogen--free conditions. Foxp3YFP-Cre^+^ mice were purchased from the Jackson laboratory ([@R33]) and bred with Bcl11b^F/F^ mice on a C57Bl/6 background to generate (i) homozygous Bcl11b^F/F^ Foxp3YFP-Cre^+^ male mice and Bcl11b^F/F^ Foxp3YFP-Cre^+/+^ female mice (Bcl11b/T~reg~ KO), with Bcl11b deleted in all T~reg~ cells, and (ii) Bcl11b^F/F^ Foxp3YFP-Cre^+/−^ (Bcl11b/T~reg~ KO mosaic), in which in addition to Bcl11b-deficient T~reg~ cells, WT T~reg~ cells were also present. The controls for this group were Bcl11b^F/WT^ Foxp3YFP-Cre^+/−^ HT mosaic female mice. All experiments were conducted according to the animal protocols approved by the University of Florida Institutional Animal Care and Use Committee.

EAE was induced in Bcl11b^F/F^ Foxp3YFP-Cre^+/−^ (Bcl11b/T~reg~ KO mosaic) and age-matched control female mice, as previously described ([@R27]). Experiments were conducted at day 10 after induction of EAE.

Flank tumor inoculation
-----------------------

B16-Ova melanoma cells (5 × 10^5^) were injected subcutaneously in the right flank of Bcl11b/T~reg~ KO mosaic female mice, tumors were isolated on day 14, and immune cells were isolated as described below.

In vivo suppression assay
-------------------------

The in vivo suppression assay was conducted as previously described by Mottet *et al*. ([@R34]). Briefly, B6.Rag1^−/−^ mice were injected with 4 × 10^5^ CD4^+^CD45RB^hi^ from CD45.1 WT mice to induce colitis and with 1 × 10^5^ YFP^+^ T~reg~ cells from Bcl11b^F/F^ Foxp3YFP-Cre^+/−^ (Bcl11b/T~reg~ KO mosaic) (CD45.2) or from Bcl11b^F/WT^ Foxp3YFP-Cre^+/−^ (HT mosaic) (CD45.2) mice, or no additional cells. Mice were weighed twice a week.

Colitis histopathology scores
-----------------------------

Colonic tissue was removed from the mouse, and a 1.0-cm section was cut out from the distal portion of the colon, 1.5 cm away from the anus. The colon section was fixed overnight in 10% formalin and then embedded in paraffin. Sections of 5 μm were stained by H&E or Alcian Blue (pH 2.5). Colitis histopathological scores were established using the following criteria: immune infiltration---none = 0 to marked, dense infiltration = 4; extent of infiltration---none = 0 to mucosal, submucosal, and transmural = 3. Epithelial changes included hyperplasia visible as crypt elongation: none = 0 to marked = 4; goblet cell loss: none = 0 to marked = 4; and erosion as loss of surface epithelium; 0 to 4. Mucosal architecture scoring included ulceration: 3 or 4, irregular crypts: 4, and crypt loss: 0 to 4.

Cell isolation and analysis
---------------------------

Cell isolation was performed as previously described by VanValkenburgh *et al*. ([@R32]). For isolation of immune cells from B16-Ova flank tumors, tumors were excised from mice, and tissue was homogenized using the GentleMacs system on m.Tumor.01 (Miltenyi). Tissue was further incubated with collagenase D (2.0 mg/ml; Worthington) and 7.5 of μl deoxyribonuclease (Sigma-Aldrich) for 30 min at 37°C in a shaking incubator. Samples were passed through a 70-μm filter, and tumor cells were removed by a 44/66% Percoll gradient centrifugation. For intracellular and TF staining, the eBioscience Foxp3/Transcription Factor Staining Buffer Set (cat. no. 00-5523-00) was used. Flow cytometry was performed on a BD LSR II, data acquisition was performed on BD FACSDiva Software, and flow cytometry files were analyzed on FlowJo. Antibodies are listed in table S4.

RNA-seq library preparation and data processing
-----------------------------------------------

RNA was extracted from sort-purified WT and Bcl11b KO T~reg~ cells from steady state and on day 10 after induction of EAE using the RNeasy Plus Micro Kit (74034, Qiagen), and ribosomal RNA (rRNA) was depleted using NEBNext rRNA Depletion Kit (E63102, New England Biolabs). Complementary DNA libraries were prepared using NEBNext Ultra II RNA Library Prep Kit (E7770S, New England Biolabs) and sequenced on a NextSeq 500 at approximately 30 million reads per library ([@R28]). RNA-seq fastq files were trimmed using seqtk, and the quality was assessed using FastQC ([@R28]). The trimmed reads were aligned to the mouse genome (mm10) using Hisat2, and transcript counts were obtained using HTseq ([@R28]). DeSeq2 was used for differential expression analysis ([@R40]).

Assay for transposase-accessible chromatin sequencing
-----------------------------------------------------

ATAC-seq was performed as previously described ([@R28], [@R36]) on 50,000 sort-purified YFP^+^ T~reg~ cells from Bcl11b/T~reg~ KO and HT mosaic mice. Library quality and adapter dimer contamination were assessed on a Bioanalyzer (\#5067-4626, Agilent). Libraries were sequenced as PE75 on a NextSeq500.

Bcl11b ChIP-seq
---------------

T~reg~ cells were isolated from the spleens and peLNs of naïve mice and enriched using the EasySep Mouse CD4^+^ CD25^+^ Regulatory T Cell Isolation Kit II (\#18783, STEMCELL). Human T~reg~ cells were isolated from PBMCs by sorting CD4^+^ CD25^+^ CD127^−^ cells. Bcl11b ChIP-seq was performed on T~reg~ cells using the SimpleChIP Enzymatic Chromatin IP Kit from Cell Signaling Technology (CST \#9003), following their recommended protocol up to the library preparation with the following alterations: (i) 10^7^ cells were used in place of 4 × 10^7^, (ii) formaldehyde fixation was performed in 1 ml, (iii) buffer A and B steps were all performed in 1 ml, (iv) cells were sheared in ChIP buffer to an average of 200 to 1000 base pairs using a Diagenode Bioruptor Pico (B01060002), (v) a cocktail of three anti-Bcl11b antibodies were used (4 μg of ab18465, 4 μg of CST \#12120, and 4 μg of Bethyl A300-385 per ChIP), and (vi) final DNA purification was performed by phenol:chloroform:isoamyl alcohol extraction and MaXtract high-density columns (\#129046, Qiagen). Libraries were prepared using NEBNext Ultra II DNA Library Prep Kit (\#E7645S, New England Biolabs) and sequenced as SE75 on a NextSeq500.

ATAC-seq and ChIP-seq data processing
-------------------------------------

Data analysis for ATAC-seq was performed using a customized pipeline based on a previously published version ([@R28], [@R41]). Briefly, fastq files were first trimmed using Trimmomatic, and read quality was assessed using FastQC. Reads were aligned to the mouse genome (mm10) using Bowtie2. The resulting SAM file was pruned (*Q* \> 30), converted to BAM format, and sorted using SAMtools. Duplicate reads were removed using Picard tools, and MACS2 was used for peak calling and bedgraph file preparation. Bedgraph files were visualized using IGV. ChIP-seq data were analyzed as ATAC-seq except using single-end rather than paired-end settings. Differential chromatin accessibility was conducted using MAnorm with the cutoff set at a minimum fold change of 2 and significance of *P* \< 0.05. *P* value was adjusted for the FDR by the Benjamini-Hochberg adjustment.

Proximity ligation assay
------------------------

PLA was conducted by the Duolink PLA--fluorescence-activated cell sorting (FACS) protocol (Sigma-Aldrich). Briefly, WT T~reg~ cells were isolated using the EasySep Mouse CD4^+^ CD25^+^ Regulatory T Cell Kit II (\#18783, STEMCELL). CD4^+^ T cells were sorted and isolated from the negative fraction after CD25^+^ selection. Bcl11b KO T~reg~ cells were sorted from mosaic female mice. Cells (1 × 10^5^) were fixed in 2% paraformaldehyde for 10 min at room temperature and permeabilized with 0.5% Triton X-100 for 30 min at room temperature. Cells were incubated with rabbit anti-Bcl11b (Bethyl A300-385) and rat anti-Foxp3 antibody (126402, BioLegend) for 30 min, followed by addition of oligonucleotide (probes)--conjugated secondary antibodies against rabbit and rat, respectively. Two circle-forming oligonucleotides and a ligation enzyme were subsequently added and ligated to the probes following the Duolink PLA-FACS protocol, with the difference that the amplification was conducted overnight. Rolling circle amplification occurs only when the two probes are \<40 nm apart, and fluorescently labeled complementary oligonucleotides bind to the amplified DNA, allowing detection by FACS.

Motif enrichment between activated and repressed genes
------------------------------------------------------

Bcl11b ChIP-seq peaks were annotated to genes using HOMER and matched to significantly up-regulated or down-regulated genes. Motif analysis was conducted on each peak set using HOMER. The top 10 known motifs from activated or repressed gene sets were further analyzed. Fisher's exact test was conducted to determine whether each motif was significantly enriched in either the up-regulated or down-regulated gene set.

Correlation analysis between steady-state and EAE RNA-seq
---------------------------------------------------------

All differentially expressed genes log~2~ (fold change) between WT and KO T~reg~ cells at steady state and EAE were paired. These paired values were subsequently matched to the gene lists for pathways enriched by GSEA and used to calculate Spearman correlations for each gene list.

Statistics
----------

For nonsequencing experiments, three or more mice per group were used, and the experiments were repeated at least three times independently. For YFP^+^ Bcl11b KO T~reg~ cells and YFP^−^ WT T~reg~ cells from the same mouse, paired Student's *t* test was used for statistical analysis, and *P* \< 0.05 was considered significant. In experiments where single comparisons were made across different mice, two-tailed Student's *t* test was used for statistical analysis, and *P* \< 0.05 was considered significant. In the case of multiple groups of mice of different genotypes, we used an analysis of variance (ANOVA) or a Kruskal-Wallis test applicable for continuous variables. Significance for RNA-seq data was determined using DeSeq2, using *P* \< 0.05 and adjusting for the FDR by Benjamini-Hochberg adjustment.
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